Alcami will be exhibiting at AAPS 2019 PharmSci 360, to be held November 3 - 6 in San Antonio, Texas. Schedule a meeting or stop by booth #1511 to connect with our team.

Alcami will be exhibiting at CPhI Worldwide, to be held November 5 - 7 in Frankfurt, Germany. Schedule a meeting or stop by booth #121C31 to connect with our team.

Alcami will be attending BIO International Convention, to be held June 3 - 6, 2019 in Philadelphia, PA.

Be sure to stop by Booth #3401 and connect with the Alcami team.

Name: Bhadresh Nayee
Alcami Site: Edison, NJ

How long have you been with Alcami?
I have been with Alcami since 2007.

What is your role? 
I’m working as a microbiology analyst at our Edison, New Jersey site. My day-to-day activities involve antibiotic testing, container closure integrity testing, and isolating/creating cultures of bacteria to study the impact of these microorganisms in order to obtain information on types and levels of microbial contamination.

What is the most rewarding part of your job?
The most rewarding part of my job is our clients' satisfaction from my work.

Alcami recently contributed to an article in the Greater Wilmington Business Journal titled, "Overcoming the Opioid Overdose Crisis."

Our community has come together, like many others, to combat the opioid crisis. Several local agencies have rallied to create impactful community resources. A 2016 survey by Castlight, which listed Wilmington, NC as the #1 city for opioid abuse in the United States, was a wake-up call to the level of severity this community has been affected by opioid-related fatalities and hardships. At Alcami, we work with our clients to develop abuse deterrence medicines to help combat this nationwide epidemic that hits home, even here in Wilmington.

Over the years, the US Pharmacopeia (USP), International Harmonisation (ICH), Product Quality Research Institute (PQRI), and several other industry consortia have developed guidelines and best practices for these extractables & leachables studies.

Alcami has specialized knowledge of the most common materials of construction such as platinum-cured silicon, halobutyl rubber, cyclic olefins, polyethylene terephthalate (PET), polyvinyl chloride (PVC), and other elastomers. Vial and stopper configurations, spray pumps, and intravenous (IV) bags are among the most common packaging system components we evaluate. We welcome all routes of administration, including the more challenging prefilled syringes, blow-fill sealed vials, and laminated cans.

Name: Czarina Carino
Alcami Site: Durham, NC

How long have you been with Alcami?
It will be my 11th year with Alcami in June.

What is your role? 
I am a scientist in the pharmaceutical development laboratory at our Durham, North Carolina site. I evaluate, develop, validate test methods, perform abuse deterrence studies, and train analysts in specialized analytical methods.

What is the most rewarding part of your job?
The most rewarding part of my job is completing and executing a test successfully– be it an evaluation, development, validation, or a special research project– because a successful execution entails a lot of things– company filing a new drug application (NDA) on time; a timely manufacture of a drug product; sharing experiences and knowledge; contributing to the site’s goals, and most of all, helping to ensure that a product delivered to the patient is safe, has integrity, and is of high quality.

Alcami will be exhibiting and presenting at CPhI North America, to be held April 30 - May 2, 2019 in Chicago, IL. Be sure to stop by booth #402 and connect with the Alcami team.

 And don't miss the following Alcami presentations:

Alcami parenteral experts recently contributed to an article in Pharmaceutical Outsourcing titled, "An Interview with Alcami."

As new parenteral products are introduced into the market, what are some of the challenges parenteral manufacturers have faced, and how do they solve these challenges?

If current trends hold, it is expected that new parenteral products will be increasingly complex, requiring nonstandard manufacturing technologies subjected to higher standards of regulatory scrutiny and market expectations. With the emphasis on precision medicine— an emerging approach of disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person— there will be a greater number of biologic drugs, multidrug combination products, drug device combinations, and targeted drug delivery systems introduced to the market. Parenteral manufacturing of these complex drug products will require special equipment, technologies, and control strategies. It will also require highly skilled process engineers, manufacturing operators, and quality assurance personnel. 

Alcami recently contributed to an article in Contract Pharma titled "Oral Solids Endure & Evolve."

Contract Pharma talks with several contract service providers about the state of the oral solid dose development and manufacturing market.

The oral solid dose (OSD) development through manufacturing pipeline of products is expanding at a robust rate—even while industry watches the investment, interest and demand for biologics and biosimilars growing rapidly. There are several reasons OSDs continue to be the most popular dosage form for getting drugs to patients. In addition to being cost effective and relatively easy to make compared to their large molecule counterparts, they are most importantly, patient friendly, especially among the pediatric and geriatric populations.